Quantics has been supporting our clients

in all statistical aspects of clinical trials since 2002

Quantics can support you through
all clinical phases.

Clinical Trial Phases

PK & PD Studies

More

Sample Size Calculation

More

Final Study Reporting

More

Adaptive Design

More

Regulatory Submission Support

More

Survival Analysis

More

Study Design

More

Independent Protocol Review

More

CDISC Reporting

More

Interim Safety Analysis

More

Independent Statistical Analysis Review

More

Health Technology Assessment

More

PK & PD Analysis

Quantics can undertake  PK / PD analyses to GCP standard (or GLP).

We can analyse as appropriate all the standard parameters including:

Cmax

MRT

T 1/2

tmax

CL

Lambda-z

AUC

Vss

PK Graph

Study Design

Quantics is very experienced in many different types of study design, in many different clinical areas including respiratory, oncology, dermatology, cardiovascular and gastro-intestinal. 

We can provide a report on the pros and cons of particular designs including adaptive models and other complex designs to ensure that the trial gains the maximum information at minimum cost.

Complex Study Designs

We have particular experience in sample size estimation in complex study designs.

Sample-Size

Sample Size Calculation

Sample size calculations are vital to clinical trials. With average per patient costs of a Phase 3 trial of $40,000, minimising the numbers required is very important. Too big a sample wastes time and money, but reducing the number too far may result in the entire trial being wasted.

Sample size calculations are based on a set of assumptions about what the trial is expected to show, based on historical data. Quantics has extensive experience in this field, and can provide a comprehensive report on the impact of varying the assumptions on the sample size and likely trial success, enabling you to balance the risk of trial failure against cost and recruitment time. We can explain the options with risks and consequences in ways suitable for scientists and financial supporters.

We have experience to help you in all of the following areas:

Exploratory studies / descriptive studies

Non-inferiority or superiority studies

  • Choice and justification for non-inferiority margin

Adaptive designs

Designs involving data monitoring committees and interim analysis

  • Impact of data monitoring committee decisions or interim analyses  on sample size (power) of the study – does it need to be modified?
  • Stopping rules

Adaptive Design

If there is not enough historical evidence about the expected performance of a clinical trial to be reasonably confident in the design, an adaptive trial can be designed. An adaptive trial monitors the outcomes of interest as the trial progresses, and uses this information to adjust trial parameters such as sample size, prescribing schedule, doses used, or patient selection criteria.

If this is to be done, the adaptive process MUST be fully defined in the protocol prior to the trial start and can not be subsequently changed.

Details of the adaptive process  need to be masked from investigators to maintain blinding and Quantics, as an independent statistical consultancy, can design, monitor analyse and direct changes for an adaptive trial without risk of un-blinding.

adaptive-design chart

CDISC Reporting

Quantics can undertake full trial statistical analysis and provide appropriate reports for the Final Study Report, all to CDISC and GCP standards.

We can work with SDTM data from Data Management companies, provide ADaM and define.doc data sets, and all required documentation.

CDISC-LOGO

Saving You Time & Money

Quantics uses unique Diverse Self-Checking Pair (DSCP) programming (note that DSCP is not the same as “double programming”).

DSCP drastically reduces the QA and QC time at the end of the study, minimising the time from database lock to final results.

Interim-Safety-report

Interim Safety Analysis

Interim analyses and data monitoring committee meetings need to be planned and defined in the SAP. In particular it is important to define what data is to be reported, whether it is to be unblinded, and how the consequences of any decisions made will be implemented, and what the implications may be on the power of the study and required sample size.

Quantics can provide completely independent analysis, allowing unblinded results to to be examined without risk of unblinding of investigational staff. Quantics staff can also be part of the review group if required.

Independent Review

Quantics can provide a completely independent review of CRO proposals to address your core concerns:

  • Is the overall study design appropriate for the objectives?
  • Is the protocol sufficiently consistent and well specified to allow results to be calculated without ambiguity?
  • Is the SAP consistent with the protocol and are the techniques proposed appropriate?
  • Does the SAP specify management of special aspects such as population groups, missing data?
  • If a data monitoring committee or interim analysis is planned,
    • Are the requirements specified?
    • Has management of consequent decisions been specified?
  • Does the CRF capture the information required for the analysis?
  • Is the information captured by the CRF in the most efficient form for the analysis?
Clinical Trial Independent checklist

Meeting Representation

We are happy to represent you at face to face meetings if required.

Regulatory Submission Support

Quantics has extensive experience discussing statistical issues raised in the design stage or at NDA stage with regulators including MHRA,FDA, EMA, PMDA.